New Efficacy Data Shared at ACVS 2015 on Post-Surgical Pain Therapeutic for Dogs

Aratana Therapeutics, Inc., a pet therapeutics company focused on licensing, developing and commercializing innovative biopharmaceutical products for cats and dogs, shared findings at the 2015 American College of Veterinary Surgeon’s (ACVS) Surgery Summit in Nashville, Tennessee October 21-24 from a pilot clinical field study evaluating effectiveness and duration of bupivacaine liposome injectable suspension (AT-003) as an option for post-surgical analgesia in dogs that underwent stifle surgery.

Drs. Duncan Lascelles, BSc, BVSc, PhD, CertVA, DSAS (ST), DECVS, DACVS, MRCVS (North Carolina State University) and Lesley Rausch-Derra, DVM (Aratana Therapeutics) presented a prospective, masked, randomized, placebo-controlled multi-center pilot field study evaluating surgical site infiltration with bupivacaine liposome injectable suspension (AT-003) in dogs undergoing lateral retinacular suture placement for cranial cruciate insufficiency. Results showed bupivacaine liposome injectable suspension (AT-003) provided pain relief over a 72 hour period following surgery when compared to placebo and the therapeutic was well-tolerated.

Aratana sponsored a lunch session on a new therapeutic advance for dogs with osteosarcoma, featuring Nicola Mason, BVetMed, PhD, DACVIM (SAIM) (University of Pennsylvania) and Nicole Ehrhart, VMD, MS, DACVS (Colorado State University) as keynote speakers. The Company also arranged a breakfast session with Kristin Kirkby Shaw, DVM, MS, PhD, DACVS, DACVSMR (Animal Surgical Clinic of Seattle) discussed a new novel therapeutic for osteoarthritis in dogs and cats, along with Dr. Lascelles sharing how new therapeutic options for post-operative pain in dogs and cats are providing extended pain relief.

“Our pilot field study data presented at ACVS showed bupivacaine liposome injectable suspension (AT-003) offered pain relief and was well-tolerated in dogs undergoing a specific surgery, which further validates our continued research to develop this product for clinical use,” stated Steven St. Peter, M.D., President and Chief Executive Officer.

Our next conference update will be from the North American Veterinary Community Conference (NAVC) in Orlando, Florida January 16-20.


Recent News Posts

View All